Abivax S.A. (ABVX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Abivax S.A. (ABVX) Healthcare & Pipeline Overview

Abivax S.A. is a French biotechnology company specializing in the discovery and optimization of drugs for inflammatory, infectious diseases, and cancer. With its lead compound ABX464 in Phase IIb clinical trials for ulcerative colitis and Crohn's Disease, and ABX 196 targeting hepatocellular cancer, the company focuses on advancing novel therapeutic candidates through various clinical stages.

What Is the Investment Thesis for ABVX?

Abivax S.A. presents a research-driven profile within the biotechnology sector, characterized by its focus on developing novel drug candidates for inflammatory diseases, infectious diseases, and cancer. The primary value driver is ABX464, currently in Phase IIb clinical trials for ulcerative colitis and Crohn's Disease, and Phase IIa for rheumatoid arthritis. Positive outcomes from these late-stage trials, particularly the Phase IIb results, represent significant upcoming catalysts that could substantially de-risk the asset and enhance its market potential. The successful completion of Phase IIa for HIV viral remission also highlights ABX464's versatility. Additionally, ABX 196, an immune enhancer in Phase 1/2 for hepatocellular cancer, offers diversification into the oncology market. With a market capitalization of $8.51B, the company's valuation is largely tied to the clinical progression and eventual commercialization prospects of its pipeline. Key risks include the inherent uncertainties of clinical development, potential regulatory hurdles, and the competitive landscape in its targeted therapeutic areas. The company's negative Beta of -0.19 suggests a low correlation with broader market movements, which is typical for early-stage biotech firms whose fortunes are more tied to specific pipeline milestones.

Based on FMP financials and quantitative analysis

ABVX Key Highlights

Market capitalization of $8.51B, reflecting its current valuation in the biotechnology sector.

• Beta of -0.19, indicating a low correlation with broader market movements, typical for development-stage biotech companies.
• Lead product ABX464 is in Phase IIb clinical trials for ulcerative colitis and Crohn's Disease, targeting significant inflammatory conditions.
• Pipeline includes ABX 196, an immune enhancer candidate in Phase 1/2 clinical trials for hepatocellular cancer, diversifying its therapeutic focus.
• Engages in early-stage research programs for infectious diseases such as Dengue fever, influenza, and respiratory syncytial virus.

Who Are ABVX's Competitors?

ABVX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ABVX's Key Strengths?

Diverse clinical pipeline with lead candidate ABX464 targeting multiple significant indications (ulcerative colitis, Crohn's, rheumatoid arthritis, HIV).

• Strategic license contracts with prominent French research institutions, enhancing R&D capabilities and intellectual property.
• Focus on therapeutic areas with high unmet medical needs, including inflammatory diseases, infectious diseases, and cancer.
• ABX 196 provides pipeline diversification into the oncology market with an immune enhancer candidate.

What Are ABVX's Weaknesses?

No commercialized products currently, making the company entirely dependent on pipeline success.

• Relatively small employee base (69 employees) for a company with a broad therapeutic focus, potentially limiting internal capacity.
• High capital requirements for ongoing research and development, necessitating future financing.
• Early-stage nature of some pipeline candidates (e.g., ABX 196 in Phase 1/2, early research programs).

What Could Drive ABVX Stock Higher?

ABVX catalyst: Results from ABX464 Phase IIb clinical trials for ulcerative colitis and Crohn's Disease, which are critical for advancing the lead candidate.

• Initiation of Phase III clinical trials for ABX464 in ulcerative colitis or Crohn's Disease, contingent on positive Phase IIb data and regulatory discussions.
• Publication of results from ABX464 Phase IIa clinical trials for rheumatoid arthritis, which could expand the drug's potential market.
• Continued progress and data readouts from ABX 196 Phase 1/2 clinical trials for hepatocellular cancer, validating its immune enhancer potential.

What Are the Key Risks for ABVX?

Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures, particularly for lead candidate ABX464, which could significantly impact the company's valuation and future prospects.
• Regulatory approval challenges, including delays or outright rejections by health authorities, which are common in the biotechnology sector.
• Intense competition from established pharmaceutical companies and other biotechnology firms developing treatments for inflammatory diseases, infectious diseases, and cancer.
• Significant capital requirements for continued research and development, necessitating future financing rounds that could dilute existing shareholders.
• Intellectual property disputes or challenges to patent protection for its proprietary drug candidates, potentially impacting market exclusivity.

What Are the Growth Opportunities for ABVX?

• Advancement of ABX464 for Ulcerative Colitis and Crohn's Disease: ABX464 is currently in Phase IIb clinical trials for these chronic inflammatory bowel diseases, representing a significant growth opportunity. The market for inflammatory bowel disease treatments is substantial and growing, driven by increasing diagnosis rates and the need for more effective, long-term therapies. Positive results from these late-stage trials could pave the way for Phase III development and eventual regulatory approval, potentially positioning ABX464 as a novel treatment option in a multi-billion dollar market. The timeline for these developments would span several years, contingent on clinical success and regulatory review.
• Expansion of ABX464 into Rheumatoid Arthritis: The development of ABX464 in Phase IIa clinical trials for rheumatoid arthritis targets another large and underserved inflammatory disease market. Rheumatoid arthritis affects millions globally, and while existing treatments are available, there remains a demand for therapies with improved efficacy, safety profiles, or novel mechanisms of action. Successful progression through clinical development for this indication could significantly broaden Abivax S.A.'s addressable market and diversify its pipeline's potential revenue streams. This opportunity would unfold over an intermediate to long-term horizon, subject to trial outcomes.
• Development of ABX 196 for Hepatocellular Cancer: ABX 196, an immune enhancer candidate, is in Phase 1/2 clinical trials for hepatocellular cancer (HCC). HCC represents a challenging oncology indication with high unmet medical need and a growing incidence worldwide. The global market for liver cancer therapeutics is projected to expand, driven by advancements in immunotherapy and targeted therapies. Successful clinical development of ABX 196 could position Abivax S.A. within the lucrative oncology market, offering a potentially innovative approach to treating this aggressive cancer. The timeline for market entry would be long-term, given its current early clinical stage.
• Potential for ABX464 in HIV Viral Remission: Having completed Phase IIa clinical trials for viral remission in patients with HIV, ABX464 demonstrates potential in a critical infectious disease area. While current HIV treatments effectively suppress the virus, a functional cure or sustained viral remission without daily medication remains a significant medical goal. Further development of ABX464 in this indication could tap into a global market seeking transformative HIV therapies, potentially offering a differentiated approach beyond lifelong antiretroviral therapy. This represents a long-term growth opportunity, contingent on further clinical validation.
• Advancement of Early-Stage Research Programs: Abivax S.A. is also engaged in research programs for other infectious diseases, including Dengue fever, influenza, and respiratory syncytial virus (RSV). These represent substantial global health threats with ongoing needs for improved prophylactic and therapeutic interventions. While these programs are in early stages, successful preclinical and early clinical development could lead to a diversified pipeline beyond current lead candidates. These programs offer long-term growth potential by addressing emerging and persistent infectious disease challenges, contributing to the company's future product portfolio and market reach.

What Threats Does ABVX Face?

• High risk of clinical trial failures, which could lead to significant value erosion and pipeline setbacks.
• Intense competition from established pharmaceutical companies and other biotechnology firms in its targeted therapeutic areas.
• Stringent and unpredictable regulatory approval processes, potentially causing delays or outright rejections.
• Reliance on intellectual property protection, which could be challenged or infringed upon by competitors.

What Are ABVX's Competitive Advantages?

• Proprietary drug candidates, such as ABX464 and ABX 196, with novel mechanisms of action.
• Intellectual property protection derived from its research and license contracts with leading scientific institutions.
• Specialized R&D expertise in specific therapeutic areas, enabling targeted drug discovery.
• Progress through clinical trial stages, which de-risks assets and creates barriers to entry for competitors.

What Does ABVX Do?

Abivax S.A., incorporated in 2013 and headquartered in Paris, France, is a biotechnology company dedicated to the discovery and optimization of novel drugs addressing significant unmet medical needs in inflammatory diseases, infectious diseases, and cancer. The company's strategic focus involves advancing a pipeline of proprietary compounds through various phases of clinical development. Its flagship product, ABX464, represents a key asset, currently undergoing rigorous evaluation in multiple therapeutic indications. Specifically, ABX464 is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, two chronic inflammatory bowel conditions with substantial patient populations. Furthermore, ABX464 is also being investigated in Phase IIa clinical trials for rheumatoid arthritis, another prevalent autoimmune inflammatory disorder. The compound has also demonstrated progress in the infectious disease arena, having completed a Phase IIa clinical trial for the treatment of viral remission in patients with HIV, indicating its broad therapeutic potential. Beyond ABX464, Abivax S.A. is developing ABX 196, an immune enhancer candidate, which is currently in Phase 1/2 clinical trials for the treatment of hepatocellular cancer, a challenging malignancy. The company's research endeavors extend to earlier-stage programs, including investigations into treatments for Dengue fever, influenza, and respiratory syncytial virus, reflecting a commitment to addressing a wide spectrum of global health challenges. Abivax S.A. operates with a lean team of 69 employees, leveraging its scientific expertise and strategic collaborations. The company has established important license contracts with prominent French research institutions, including the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie, which are instrumental in supporting its drug discovery and development efforts. This collaborative approach underpins its strategy to bring innovative therapies to market.

What Products and Services Does ABVX Offer?

• Discover and optimize drugs for inflammatory diseases.
• Discover and optimize drugs for infectious diseases.
• Discover and optimize drugs for cancer.
• Develop ABX464 for ulcerative colitis, Crohn's Disease, COVID-19, rheumatoid arthritis, and HIV viral remission.
• Develop ABX 196 as an immune enhancer for hepatocellular cancer.
• Conduct research programs for Dengue fever, influenza, and respiratory syncytial virus.
• Hold license contracts with leading French research institutions like the French National Centre for Scientific Research, University of Montpellier, and Institut Curie.

How Does ABVX Make Money?

• Operates as a research and development-focused biotechnology company.
• Generates value through the discovery, clinical development, and potential commercialization or out-licensing of proprietary drug candidates.
• Leverages intellectual property and scientific expertise gained through internal research and external license contracts with academic institutions.

What Industry Does ABVX Operate In?

Abivax S.A. operates within the highly specialized and capital-intensive biotechnology industry, a sub-sector of Healthcare. This industry is characterized by extensive research and development efforts, long drug development cycles, and stringent regulatory approval processes. Abivax S.A. positions itself by focusing on therapeutic areas with significant unmet medical needs, including inflammatory diseases, infectious diseases, and cancer. The global market for these diseases is substantial, driven by aging populations, increasing prevalence, and demand for more effective treatments. The competitive landscape is intense, featuring both large pharmaceutical companies and numerous smaller biotech firms. Abivax S.A. differentiates itself through its proprietary compounds like ABX464 and ABX 196, aiming to offer novel mechanisms of action. Peers such as Jazz Pharmaceuticals plc, Axsome Therapeutics, Inc., Madrigal Pharmaceuticals, Inc., Nuvalent, Inc., and Corcept Therapeutics Incorporated represent various segments of the biotech and specialty pharma markets, indicating a diverse competitive environment where innovation and clinical success are paramount for market positioning and growth.

Who Are ABVX's Key Customers?

• Ultimately, patients suffering from inflammatory diseases, infectious diseases, and cancer worldwide.
• Healthcare providers and medical institutions seeking advanced therapeutic options.
• Potential pharmaceutical partners for licensing, co-development, or commercialization agreements.

Wall Street analysts project Abivax S.A. revenue of about $3.8M for fiscal 2026, with EPS near $-3.30. The estimate reflects 10 contributing analysts.

Quarterly Financial Performance: Abivax S.A.

Revenue for Abivax S.A. came in at $0 during Q4 FY2025. The company recorded a net loss of $287.7M, with diluted EPS of $-4.14. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, ABVX averaged $-1.59 in diluted EPS.

ABVX Valuation & Market Position

With a $8.51B market cap, Abivax S.A. sits in the mid-cap segment of the market. Analyst price targets span from $90.00 to $180.00, with a consensus of $153.00. At the current price of $115.95, that implies approximately 32% upside potential. Relative to its peer group, ABVX's quantitative score of 55/100 is roughly in line with the peer average of 57/100.

Key Financial Metrics

Return on assets is -57.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.75 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.3%, the inverse of the P/E and a quick read on earnings relative to price.

Abivax S.A.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 28.70 places it in the safe zone, indicating low near-term bankruptcy risk.

Abivax S.A. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 34.3% below estimates on average.

Company Profile

Abivax S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Paris, FR. The company is led by CEO Marc de Garidel. ABVX has traded publicly since 2023.

ABVX Financials

ABVX Latest News

ABVX Analyst Consensus

ABVX MoonshotScore

Abivax S.A. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources